A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
About this item
Full title
Author / Creator
DESCARTES Investigators , Blom, Dirk J , Hala, Tomas , Bolognese, Michael , Lillestol, Michael J , Toth, Phillip D , Burgess, Lesley , Ceska, Richard , Roth, Eli , Koren, Michael J , Ballantyne, Christie M , Monsalvo, Maria Laura , Tsirtsonis, Kate , Kim, Jae B , Scott, Rob , Wasserman, Scott M and Stein, Evan A
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Patients with hyperlipidemia were assigned to receive the PCSK9 antibody evolocumab or placebo on a background of lipid-lowering therapy. At 52 weeks, the least-squares mean reduction in LDL cholesterol from baseline for evolocumab versus placebo was 57%.
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that is produced p...
Alternative Titles
Full title
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1523405745
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1523405745
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1316222
